Literature DB >> 6404326

Monitoring the entry of new platelets into the circulation after ingestion of aspirin.

G Di Minno, M J Silver, S Murphy.   

Abstract

There have been reports of a 24-48-hr delay in the recovery of platelet cyclooxygenase activity and platelet function after the ingestion of aspirin. However, these studies employed a single aggregating agent to stimulate enzymatic or functional activity. We investigated the effects of some pairs of aggregating agents on 14 platelet-rich plasmas (PRP) from normal subjects 2 and 4 hr after ingestion of 650 mg aspirin and daily up to 72 hr. We studied platelet aggregation and secretion with a lumiaggregometer and thromboxane-B2 formation by radioimmunoassay. Aggregation and secretion occurred as early as 4 hr after aspirin ingestion in response to combinations of arachidonic acid with epinephrine, collagen, or adenosine diphosphate (ADP). Thromboxane formation was detected as early as 4 hr after ingestion of aspirin in response to 1 mM arachidonic acid in combination with 1 microgram/ml collagen. Up to 72 hr, there was a linear return of thromboxane formation stimulated by this combination, reflecting the entry of new platelets into the circulation. In vitro experiments with mixtures of aspirin-free and aspirin-treated platelets showed that the combination of collagen and arachidonic acid (AA) could produce full aggregation and secretion when only 2.5% of aspirin-free platelets were present. Use of the combination of collagen plus AA demonstrates the early entry into the circulation of platelets originating from megakaryocytes whose cyclooxygenase has not been completely acetylated.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6404326

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  22 in total

Review 1.  Current concepts for a drug-induced inhibition of formation and action of thromboxane A2.

Authors:  H Patscheke
Journal:  Blut       Date:  1990-05

2.  Role of proaggregatory and antiaggregatory prostaglandins in hemostasis. Studies with combined thromboxane synthase inhibition and thromboxane receptor antagonism.

Authors:  P Gresele; J Arnout; H Deckmyn; E Huybrechts; G Pieters; J Vermylen
Journal:  J Clin Invest       Date:  1987-11       Impact factor: 14.808

3.  Biosynthesis of thromboxane in patients with systemic sclerosis and Raynaud's phenomenon.

Authors:  I A Reilly; L Roy; G A Fitzgerald
Journal:  Br Med J (Clin Res Ed)       Date:  1986-04-19

Review 4.  Aspirin for myocardial infarction. Clinical pharmacokinetic considerations.

Authors:  F Bochner; J V Lloyd
Journal:  Clin Pharmacokinet       Date:  1995-06       Impact factor: 6.447

5.  The effects of varying doses of aspirin on human platelet activation induced by PAF, collagen and arachidonic acid.

Authors:  M L Taylor; N L Misso; G A Stewart; P J Thompson
Journal:  Br J Clin Pharmacol       Date:  1992-01       Impact factor: 4.335

Review 6.  Current issues in thrombosis prevention with antiplatelet drugs.

Authors:  G de Gaetano; C Cerletti; E Dejana; J Vermylen
Journal:  Drugs       Date:  1986-06       Impact factor: 9.546

Review 7.  Nabumetone: therapeutic use and safety profile in the management of osteoarthritis and rheumatoid arthritis.

Authors:  Thomas Hedner; Ola Samulesson; Peter Währborg; Hans Wadenvik; Kjell-Arne Ung; Anders Ekbom
Journal:  Drugs       Date:  2004       Impact factor: 9.546

8.  Perioperative handling of patients on antiplatelet therapy with need for surgery.

Authors:  Matteo Nicola Dario Di Minno; Domenico Prisco; Anna Lilia Ruocco; Pasquale Mastronardi; Salvatore Massa; Giovanni Di Minno
Journal:  Intern Emerg Med       Date:  2009-06-16       Impact factor: 3.397

9.  Inhibition of thrombocyte aggregation by oral motapizone and other drugs.

Authors:  V Schulz; W Fischer; U Hanselle; W Huhmann; V Zietsch
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

10.  Hypotensive and antiplatelet actions of motapizone depend on dose and time after ingestion.

Authors:  V Schulz; W Fischer; U Hanselle; W Huhmann; V Zietsch
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.